Combination therapies for the treatment of advanced melanoma: A review of current evidence

Biochemistry Research International

Volumn 2014, Issue , 2014, Pages

  Voskoboynik, Mark ^a   Arkenau, Hendrik Tobias ^a  

^a Sarah Cannon Research UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897789150     PISSN: 20902247     EISSN: 20902255     Source Type: Journal    
DOI: 10.1155/2014/307059     Document Type: Review

References (33)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012 62 1 10 29 2-s2.0-84855792427 10.3322/caac.20138
2. Frei E. III, Karon M., Levin R. H., Freireich E. J., Taylor R. J., Hananian J., Selawry O., Holland J. F., Hoogstraten B., Wolman I. J., Abir E., Sawitsky A., Lee S., Mills S. D., Burgert E. O. Jr., Spurr C. L., Patterson R. B., Ebaugh F. G., James G. W. III, Moon J. H., The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 1965 26 5 642 656 2-s2.0-0013811894
3. Omholt K., Platz A., Kanter L., Ringborg U., Hansson J., NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clinical Cancer Research 2003 9 17 6483 6488 2-s2.0-0348223934 (Pubitemid 38031837)
4. Davies H., Bignell G. R., Cox C., Mutations of the BRAF gene in human cancer. Nature 2002 417 6892 949 954 10.1038/nature00766 (Pubitemid 34716871)
5. Platz A., Ringborg U., Mansson Brahme E., Lagerlof B., Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Research 1994 4 3 169 177 2-s2.0-0028362370 10.1097/00008390-199406000-00005 (Pubitemid 24208277)
6. van't Veer L. J., Burgering B. M. T., Versteeg R., Boot A. J. M., Ruiter D. J., Osanto S., Schrier P. I., Bos J. L., N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Molecular and Cellular Biology 1989 9 7 3114 3116 2-s2.0-0024407112 (Pubitemid 19163079)
7. Flaherty K. T., Infante J. R., Daud A., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England Journal of Medicine 2012 367 18 1694 1703 10.1056/NEJMoa1210093
8. Kefford R., Miller W., Tan D., Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. Journal of Clinical Oncology 2013 31, abstract 9029
9. Gonzalez R., Ribas A., Daud A., Phase IB study of vemurafenib in combination with the MEK inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7). Proceedings of the ESMO Congress 2012 Vienna, Austria
10. Chapman P. B., Hauschild A., Robert C., Haanen J. B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S. J., Sosman J. A., Kirkwood J. M., Eggermont A. M. M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R. J., Flaherty K. T., McArthur G. A., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine 2011 364 26 2507 2516 2-s2.0-79959795786 10.1056/NEJMoa1103782
11. Hauschild A., Grob J.-J., Demidov L. V., Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet 2012 380 9839 358 365 10.1016/S0140-6736(12)60868-X
12. Hodi F. S., O'Day S. J., McDermott D. F., Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77957117282 10.1056/NEJMoa1003466
13. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.-F., Testori A., Grob J.-J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H. Jr., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.-T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 2011 364 26 2517 2526 2-s2.0-79959772576 10.1056/NEJMoa1104621
14. Hamid O., Robert C., Daud A., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine 2013 369 2 134 144 10.1056/NEJMoa1305133
15. Wolchok J. D., Kluger H., Callahan M. K., Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine 2013 369 2 122 133 10.1056/NEJMoa1302369
16. Chapman P. B., Hauschild A., Robert C., Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma. Journal of Clinical Oncology 2012 30, abstract 8502
17. Sosman J. A., Kim K. B., Schuchter L., Gonzalez R., Pavlick A. C., Weber J. S., McArthur G. A., Hutson T. E., Moschos S. J., Flaherty K. T., Hersey P., Kefford R., Lawrence D., Puzanov I., Lewis K. D., Amaravadi R. K., Chmielowski B., Lawrence H. J., Shyr Y., Ye F., Li J., Nolop K. B., Lee R. J., Joe A. K., Ribas A., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England Journal of Medicine 2012 366 8 707 714 2-s2.0-84857410626 10.1056/NEJMoa1112302
18. Hauschild A., Grob J. J., Lev V., An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). Journal of Clinical Oncology 2013 31, abstract 9013
19. Su F., Viros A., Milagre C., RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. The New England Journal of Medicine 2012 366 3 207 215 10.1056/NEJMoa1105358
20. Nazarian R., Shi H., Wang Q., Kong X., Koya R. C., Lee H., Chen Z., Lee M.-K., Attar N., Sazegar H., Chodon T., Nelson S. F., McArthur G., Sosman J. A., Ribas A., Lo R. S., Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010 468 7326 973 977 2-s2.0-78650303507 10.1038/nature09626
21. Villanueva J., Vultur A., Lee J. T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A. K., Wubbenhorst B., Xu X., Gimotty P. A., Kee D., Santiago-Walker A. E., Letrero R., D'Andrea K., Pushparajan A., Hayden J. E., Brown K. D., Laquerre S., McArthur G. A., Sosman J. A., Nathanson K. L., Herlyn M., Acquired Resistance to BRAF Inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010 18 6 683 695 2-s2.0-78650008177 10.1016/j.ccr.2010.11.023
22. Atefi M., von Euw E., Attar N., Ng C., Chu C., Guo D., Nazarian R., Chmielowski B., Glaspy J. A., Comin-Anduix B., Mischel P. S., Lo R. S., Ribas A., Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS ONE 2011 6 12 2-s2.0-83355170673 10.1371/journal.pone.0028973 e28973
23. V600EB-RAF inhibition. Cancer Research 2011 71 15 5067 5074 2-s2.0-79960946383 10.1158/0008-5472.CAN-11-0140
24. Sosman J. A., Daud A., Jeffrey S., BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). Journal of Clinical Oncology 2013 31, abstract 9005
25. Dutcher J. P., Creekmore S., Weiss G. R., Margolin K., Markowitz A. B., Roper M., Parkinson D., Ciobanu N., Fisher R. I., Boldt D. H., Doroshow J. H., Rayner A. A., Hawkins M., Atkins M., A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. Journal of Clinical Oncology 1989 7 4 477 485 2-s2.0-0024544021 (Pubitemid 19098143)
26. Rosenberg S. A., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E., Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Journal of the American Medical Association 1994 271 12 907 913 2-s2.0-0028266553 10.1001/jama.271.12.907 (Pubitemid 24083215)
27. Kaufman H. L., Kirkwood J. M., Hodi F. S., The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews 2013 10 10 588 598 10.1038/nrclinonc.2013.153
28. Prieto P. A., Yang J. C., Sherry R. M., Hughes M. S., Kammula U. S., White D. E., Levy C. L., Rosenberg S. A., Phan G. Q., CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clinical Cancer Research 2012 18 7 2039 2047 2-s2.0-84859393995 10.1158/1078-0432.CCR-11-1823
29. Ribas A., Kefford R., Marshall M. A., Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. Journal of Clinical Oncology 2013 31 5 616 622 10.1200/JCO.2012.44.6112
30. Topalian S. L., Hodi F. S., Brahmer J. R., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012 366 26 2443 2454 10.1056/NEJMoa1200690
31. Brahmer J. R., Tykodi S. S., Chow L. Q. M., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine 2012 366 26 2455 2465 10.1056/NEJMoa1200694
32. Brahmer J. R., Drake C. G., Wollner I., Powderly J. D., Picus J., Sharfman W. H., Stankevich E., Pons A., Salay T. M., McMiller T. L., Gilson M. M., Wang C., Selby M., Taube J. M., Anders R., Chen L., Korman A. J., Pardoll D. M., Lowy I., Topalian S. L., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology 2010 28 19 3167 3175 2-s2.0-77954899030 10.1200/JCO.2009.26.7609
33. Ribas A., Hodi F. S., Callahan M., Hepatotoxicity with combination of vemurafenib and ipilimumab. The New England Journal of Medicine 2013 368 14 1365 1366 10.1056/NEJMc1302338